Merck's Scheuble: Being a Conglomerate Works
Executive Summary
Professor Bernhard Scheuble, PhD, chairman and CEO of Merck KGAA, explains how the German conglomerate is dealing with current pressures on its branded business, and why being diversified across ethicals, generics and fine chemicals is an advantage, not a distraction.
You may also be interested in...
NicOx/AstraZeneca: Transparency vs. Partnering
AstraZeneca's news that nitric oxide donator AZD 3582 had failed to reach a primary end-point in a Phase II trial sent originator NicOx's shares plummeting, as investors lost faith in the biotech's entire platform. NicOx is disputing the data's accuracy in an attempt to salvage investor confidence--and to survive. The events highlight the tension between Big Pharma's duties to investor transparency and to protect its biotech partners. They're also a reminder to biotechs that there's more to deals than just royalties.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
The IPO Party Is Over – How Bad Is The Hangover?
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?